NEWTON, Mass., Nov. 29, 2016 /PRNewswire/ -- Dynasil Corporation
of America (NASDAQ: DYSL) today announced that its contract
research subsidiary, RMD Inc., has received three Phase I and one
Phase II grants totaling $1.9 million
under the National Institute of Health's SBIR funding program.
"RMD world-class research continues to be at the forefront of
medical technology," said Peter
Sulick, Dynasil's CEO and President. "RMD is
developing cutting edge radiation detection materials for the
National Institute of Health. The long term goal is to
deliver lower cost, next generation medical imaging systems for
specific medical needs. For more than twenty years, RMD's
research has been instrumental in advances in medical
imagery. In addition, the application of their technology to
other important imaging applications, such as airport baggage
scanning, has greatly improved results and processing speeds in
those industries."
The Phase I awards focus on three medical imaging areas;
developing new materials to improve cardiac SPECT imaging, a new
dental X-ray imager that will have retain the high quality images
associated with digital technology, while reducing the X-ray dose a
patient receives, and a new blood flow velocimetry system for the
precise measurement of blood velocity in vivo.
The Phase II award is for a novel scintillator that converts
ionizing beta radiation into optical photons that can be used in
radioluminescence microscopy. Radioluminescence microscopy is
a newly developed method for imaging radionuclide uptake in live
single cells. This will be critical to help researchers
better understand the behavior of rare single cells such as stem
cells or drug-resistant cells.
Current methods of radiotracer imaging are limited to measuring
the average radiotracer uptake in large cell populations and, as a
result, lack the ability to quantify cell-to-cell variations.
With this new technique, it is possible to visualize
radiotracer uptake within individual cells in a fluorescence
microscope environment. The goal of this project is to
develop a revolutionary innovation in a key component used in this
technique. While it could be sometime in the future, this
does represent a unique approach to a large commercial
marketplace.
These Phase I and Phase II research projects exemplify some of
the world's most demanding medical needs," said Kanai Shah, Ph.D., President of Dynasil's RMD
subsidiary. "They capitalize on our technical and scientific
capability in the development of scintillation materials and
instrumentation. RMD is proud to partner with the National
Institute of Health on these initiatives."
About Dynasil
Dynasil Corporation of America (NASDAQ:
DYSL) develops and manufactures optics and photonics products,
optical detection and analysis technology and components for the
homeland security, medical and industrial markets. Combining
world-class expertise in research and materials science with
extensive experience in manufacturing and product development,
Dynasil is commercializing products including dual-mode radiation
detection solutions for Homeland Security and commercial
applications and sensors for non-destructive testing. Dynasil
has an impressive and growing portfolio of issued and pending U.S.
patents. The Company is based in Newton, MA, with additional operations in MA,
MN, NY, NJ and the United Kingdom.
More information about the Company is available at
www.dynasil.com.
Safe Harbor
This news release may contain
forward looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These
forward-looking statements regarding future events and our future
results are based on current expectations, estimates, forecasts,
and projections and the beliefs and assumptions of our management,
including, without limitation, our expectations regarding results
of operations, the commercialization of our technology and the
strength of our intellectual property portfolio. These
forward-looking statements may be identified by the use of words
such as "plans", "intends," "may," "could," "expect," "estimate,"
"anticipate," "continue" or similar terms, though not all
forward-looking statements contain such words. The actual
results of the future events described in such forward looking
statements could differ materially from those stated in such
forward looking statements due to a number of important factors.
These factors that could cause actual results to differ from those
anticipated or predicted include, without limitation, the size and
growth of the potential markets for our products and our ability to
serve those markets, the rate and degree of market acceptance of
any of our products, general economic conditions, costs and
availability of raw materials and management information systems,
our ability to obtain and maintain intellectual property protection
for our products, competition, the loss of key management and
technical personnel, our ability to obtain timely payment of our
invoices to governmental customers, litigation, the effect of
governmental regulatory developments, the availability of financing
sources, our ability to identify and execute on acquisition
opportunities and integrate such acquisitions into our business,
and seasonality, as well as the uncertainties set forth in
the Company's 2015 Annual Report on Form 10 K, as filed on
December 17, 2015, including the risk
factors contained in Item 1a, and from time to time in the
Company's other filings with the Securities and Exchange
Commission. The Company disclaims any intention or
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Patty
Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: (617) 668-6855
pkehe@dynasil.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dynasils-rmd-subsidiary-awarded-19-million-in-technology-development-grants-by-the-national-institute-of-health-300369648.html
SOURCE Dynasil Corporation of America